type here...

CATEGORIES

Rare and Orphan Diseases

LATEST

12Page 2 of 2

TRENDING

EDITORS CHOICE

Biotech Without Borders: Reclaiming the Wonder of Science in a Distracted Age

Gil Bashe, Medika Life Editor -
I was in the media bullpen with the team when the future arrived. The launch of Roferon-A, alpha interferon marked a watershed moment in medicine:...

Real-World Evidence Unlocks Consumer Voice to Improve Care

Gil Bashe, Medika Life Editor -
Patient Experience is the Key to Improving Drug Development and Health Care, but Are We Listening?

Purpose at the Center: Craig Martin’s “Rare” Commitment to Biopharma and Patients

Gil Bashe, Medika Life Editor -
Craig Martin is a strategic chameleon in health innovation. He is equally at home in boardrooms, nonprofit leadership, consulting and advisory roles, all with...

It’s Time to Reconsider Deadly Munchausen’s Syndrome by Proxy

Pat Farrell PhD -
The little-talked-about or diagnosed syndrome may be more prevalent in healthcare than we know.

CONNECT WITH US ON SOCIAL MEDIA

Medika Life is a unique, not-for-profit operating unit of FINN Partners and maintains an independent voice. Authors opinions may not necessarily represent those shared by FINN Partners and content cannot be promotional - rather informational centered on health issues, life science innovation, ecohealth and patient experience.

© Medika Life 2020 - 2022

Compliance

CORPORATE & MEDIA

Popular categories